Beta-thalassemia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Beta-thalassemia}} | {{Beta-thalassemia}} | ||
{{CMG}}; {{AE}} {{MHP}} | |||
==Overview== | ==Overview== | ||
Secondary prevention measures would be needed after the initiation of blood transfusions with regular monitoring of iron overload, maintaining appropriate transfusion and chelation therapy regimens, and managing potential complications such as infections or organ dysfunction | Secondary prevention measures would be needed after the initiation of blood transfusions with regular monitoring of iron overload, maintaining appropriate transfusion and [[chelation therapy]] regimens, and managing potential complications such as infections or organ dysfunction. | ||
==Secondary Prevention== | |||
Secondary prevention measures would be needed after the initiation of blood transfusions with regular monitoring of: | Secondary prevention measures would be needed after the initiation of blood transfusions with regular monitoring of: | ||
*Iron overload | *Iron overload | ||
*Maintaining appropriate transfusion | *Maintaining appropriate transfusion | ||
*Chelation therapy regimens | *[[Chelation therapy]] regimens | ||
*Managing potential complications such as infections or organ dysfunction<ref name="pmid31030806">{{cite journal |vauthors=Khandros E, Kwiatkowski JL |title=Beta Thalassemia: Monitoring and New Treatment Approaches |journal=Hematol Oncol Clin North Am |volume=33 |issue=3 |pages=339–353 |date=June 2019 |pmid=31030806 |doi=10.1016/j.hoc.2019.01.003 |url=}}</ref><ref name="pmid34738740">{{cite journal |vauthors=Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA |title=Current status of beta-thalassemia and its treatment strategies |journal=Mol Genet Genomic Med |volume=9 |issue=12 |pages=e1788 |date=December 2021 |pmid=34738740 |pmc=8683628 |doi=10.1002/mgg3.1788 |url=}}</ref>. | *Managing potential complications such as infections or organ dysfunction<ref name="pmid31030806">{{cite journal |vauthors=Khandros E, Kwiatkowski JL |title=Beta Thalassemia: Monitoring and New Treatment Approaches |journal=Hematol Oncol Clin North Am |volume=33 |issue=3 |pages=339–353 |date=June 2019 |pmid=31030806 |doi=10.1016/j.hoc.2019.01.003 |url=}}</ref><ref name="pmid34738740">{{cite journal |vauthors=Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA |title=Current status of beta-thalassemia and its treatment strategies |journal=Mol Genet Genomic Med |volume=9 |issue=12 |pages=e1788 |date=December 2021 |pmid=34738740 |pmc=8683628 |doi=10.1002/mgg3.1788 |url=}}</ref>. | ||
==References== | ==References== | ||
Latest revision as of 05:57, 25 August 2023
|
Beta-thalassemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Beta-thalassemia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Beta-thalassemia secondary prevention |
|
Risk calculators and risk factors for Beta-thalassemia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
Secondary prevention measures would be needed after the initiation of blood transfusions with regular monitoring of iron overload, maintaining appropriate transfusion and chelation therapy regimens, and managing potential complications such as infections or organ dysfunction.
Secondary Prevention
Secondary prevention measures would be needed after the initiation of blood transfusions with regular monitoring of:
- Iron overload
- Maintaining appropriate transfusion
- Chelation therapy regimens
- Managing potential complications such as infections or organ dysfunction[1][2].
References
- ↑ Khandros E, Kwiatkowski JL (June 2019). "Beta Thalassemia: Monitoring and New Treatment Approaches". Hematol Oncol Clin North Am. 33 (3): 339–353. doi:10.1016/j.hoc.2019.01.003. PMID 31030806.
- ↑ Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi S, Sadia, Irfan M, Khan MA (December 2021). "Current status of beta-thalassemia and its treatment strategies". Mol Genet Genomic Med. 9 (12): e1788. doi:10.1002/mgg3.1788. PMC 8683628 Check
|pmc=value (help). PMID 34738740 Check|pmid=value (help). Vancouver style error: initials (help)